<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Res Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Res Cardiol</journal-id><journal-title-group><journal-title>Clinical Research in Cardiology</journal-title></journal-title-group><issn pub-type="ppub">1861-0684</issn><issn pub-type="epub">1861-0692</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26493304</article-id><article-id pub-id-type="pmc">4805697</article-id><article-id pub-id-type="publisher-id">927</article-id><article-id pub-id-type="doi">10.1007/s00392-015-0927-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hobl</surname><given-names>Eva-Luise</given-names></name><address><email>eva-luise.hobl@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Reiter</surname><given-names>Birgit</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Schoergenhofer</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Schwameis</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Derhaschnig</surname><given-names>Ulla</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Lang</surname><given-names>Irene Marthe</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Stimpfl</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Jilma</surname><given-names>Bernd</given-names></name><address><phone>+43 1 40400 29900</phone><email>bernd.jilma@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria </aff><aff id="Aff2"><label/>Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria </aff><aff id="Aff3"><label/>Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2016</year></pub-date><volume>105</volume><fpage>349</fpage><lpage>355</lpage><history><date date-type="received"><day>26</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Morphine decreases the concentrations and effects of clopidogrel, which could lead to treatment failure in myocardial infarction.</p></sec><sec><title>Objectives</title><p>To clarify whether more potent P2Y<sub>12</sub>-inhibitors may provide an effective alternative, we examined drug&#x02013;drug interactions between morphine and prasugrel.</p></sec><sec><title>Methods</title><p>Twelve healthy volunteers received 60&#x000a0;mg prasugrel with placebo or 5&#x000a0;mg morphine intravenously in a randomized, double-blind, placebo-controlled, cross-over trial. Pharmacokinetics were determined by liquid chromatography tandem mass spectrometry, and prasugrel effects were measured by platelet function tests.</p></sec><sec><title>Results</title><p>Morphine neither diminished total drug exposure (AUC), which was the primary endpoint, nor significantly delayed drug absorption of prasugrel. However, morphine reduced maximal plasma concentrations (<italic>C</italic><sub>max</sub>) of prasugrel active metabolite by 31&#x000a0;% (<italic>p</italic>&#x000a0;=&#x000a0;0.019). Morphine slightly, but not significantly, delayed the onset of maximal inhibition of platelet plug formation under high shear rates (30 vs. 20&#x000a0;min). Whole blood aggregation was not influenced.</p></sec><sec><title>Conclusions</title><p>Although morphine significantly decreases the maximal plasma concentrations of prasugrel active metabolite, it does not diminish its effects on platelets to a clinically relevant degree in healthy volunteers. However, it should be considered that the observed decrease in <italic>C</italic><sub>max</sub> of prasugrel active metabolite caused by morphine co-administration may gain relevance in STEMI patients.</p><p><italic>Clinical Trial Registration</italic>: NCT01369186, EUDRA-CT#: 2010-023761-22.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Drug interactions</kwd><kwd>Morphine</kwd><kwd>Platelet function tests</kwd><kwd>Prasugrel</kwd><kwd>Vasodilator-stimulated phosphoprotein</kwd></kwd-group><funding-group><award-group><funding-source><institution>Medical-Scientific Fund of the Mayor of Vienna </institution></funding-source><award-id>15028</award-id><principal-award-recipient><name><surname>Jilma</surname><given-names>Bernd</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund (AT)</institution></institution-wrap></funding-source><award-id>SFB-54</award-id><principal-award-recipient><name><surname>Jilma</surname><given-names>Bernd</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Coronary heart disease is one of the most common causes of death worldwide and numerous publications document the permanently increasing research activity in the field of acute coronary syndromes (ACS) [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>As adenosine-5&#x02032;-diphosphate (ADP) is one of the primary mediators for platelet aggregation, the administration of P2Y<sub>12</sub>-inhibitors in combination with aspirin is a mainstay in the treatment of patients with acute coronary syndromes [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>In contrast to the extensive evidence that ADP inhibitors are beneficial in patients suffering from myocardial infarction, such data from randomized controlled trials are lacking for morphine. Interestingly, the use of morphine is associated with higher mortality in patients with non-ST-segment elevation ACS [<xref ref-type="bibr" rid="CR13">13</xref>]. While this is not a causal proof, there may be a biologically plausible cause&#x02013;effect relationship: opiates inhibit gastric emptying which delays drug absorption and may decrease peak plasma levels of peroral drugs [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Indeed, a recent randomized, controlled trial demonstrated that morphine lowers the plasma levels of clopidogrel as well as its antiplatelet effects [<xref ref-type="bibr" rid="CR15">15</xref>], which could lead to treatment failure in susceptible patients.</p><p>It can be hypothesized that more potent P2Y<sub>12</sub>-inhibitors may provide a more effective alternative to clopidogrel when morphine is given, but their interaction with morphine has to be evaluated. Whereas the prodrug clopidogrel is converted into its active metabolite by cytochrome P450 enzymes in two steps [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], prasugrel is rapidly hydrolyzed by esterases to an intermediate metabolite and requires only one further CYP-dependent oxidation step to generate its active compound [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. This produces more active metabolite [<xref ref-type="bibr" rid="CR19">19</xref>], reduces the variability in response between patients and leads to a more consistent and stronger inhibition of platelets [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. We therefore hypothesized that the observed negative interaction between morphine and clopidogrel [<xref ref-type="bibr" rid="CR15">15</xref>] may be partially mitigated when prasugrel is used instead of clopidogrel, and conducted this randomized controlled trial to investigate the effect of morphine on the pharmacodynamics and pharmacokinetics of prasugrel.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Experimental design and blood collection</title><p>A double-blind, block-randomized, placebo-controlled, cross-over trial was conducted in accordance with good clinical practice guidelines and the Declaration of Helsinki to evaluate the effects of morphine on the intestinal resorption, pharmacokinetics and pharmacodynamics of prasugrel. The study was approved by the Ethics Committee of the Medical University of Vienna and the Austrian National Competent Authority and registered at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT01369186); written informed consent was obtained from all healthy subjects (<italic>n</italic>&#x000a0;=&#x000a0;12).</p><p>Key inclusion criteria were: <underline>&#x0003e;</underline>18&#x000a0;years of age; non-pregnant; the ability to comprehend the full nature and purpose of the study. Key exclusion criteria were: intake of non-steroidal anti-inflammatory drugs or platelet inhibitors; known coagulation disorders; relevant impairment of renal or hepatic function; chronic infectious diseases (HIV, hepatitis B and C); clinically relevant abnormal laboratory values; and contraindications for prasugrel or morphine.</p><p>Secretaries conducted randomization by <ext-link ext-link-type="uri" xlink:href="http://www.randomization.com">www.randomization.com</ext-link>, and prepared individually sealed opaque envelops. Morphine (5&#x000a0;mg i.v. bolus; Vendal, G.L. Pharma, Lannach, Austria) or placebo (0.9&#x000a0;% NaCl) were prepared by unblinded pharmacists and injected by blinded physicians. A minimum wash-out period of 14&#x000a0;days was chosen (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) because it exceeds platelet survival in vivo and because the effect of P2Y<sub>12</sub>-inhibition diminishes within 5&#x000a0;days [<xref ref-type="bibr" rid="CR25">25</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Schematic of trial design</p></caption><graphic xlink:href="392_2015_927_Fig1_HTML" id="MO1"/></fig></p><p>After an overnight fast, a loading dose of 60&#x000a0;mg prasugrel (Efient, Eli Lilly, Vienna, Austria) was administered with 250&#x000a0;mL tap water immediately after the injection of placebo or morphine. No food, drink or tobacco was permitted for 4&#x000a0;h.</p><p>Blood sampling times for pharmacodynamic and pharmacokinetic evaluations after study drug administration were 5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 180, 240 and 360&#x000a0;min (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig4" ref-type="fig">4</xref>). Blood was collected using an i.v. catheter after drawing a waste sample. The analysts were also blinded with regard to the sequence of periods.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Morphine lowers maximum plasma concentrations of prasugrel active metabolite. Healthy volunteers (<italic>n</italic>&#x000a0;=&#x000a0;12) received a 60&#x000a0;mg loading dose concomitantly with a placebo or 5&#x000a0;mg morphine. Data present means&#x000a0;&#x000b1;&#x000a0;95&#x000a0;% CI. <italic>p</italic> values for the comparisons between placebo and morphine: AUC 0.239; <italic>C</italic>
<sub>max</sub> 0.019*; <italic>T</italic>
<sub>max</sub> 0.798 (*indicates significance)</p></caption><graphic xlink:href="392_2015_927_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Morphine does not retard or decrease prasugrel effects to a clinically relevant degree. Adenosine diphosphate-induced aggregation was measured by whole blood aggregometry (<italic>n</italic>&#x000a0;=&#x000a0;12) and with the P2Y-cartridge of the platelet function analyzer (<italic>n</italic>&#x000a0;=&#x000a0;12). Since significance is lost after correction for multiple comparisons, at none of the time points there was a significant difference between placebo and morphine. Data present means&#x000a0;&#x000b1;&#x000a0;95&#x000a0;% CI</p></caption><graphic xlink:href="392_2015_927_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Morphine does not blunt prasugrel effects. <italic>Box- and whisker plot</italic> of the vasodilator-stimulated phosphoprotein (VASP) phosphorylation (<bold>a</bold>) and the collagen adenosine diphosphate closure time (CADP-CT) (<bold>b</bold>) 0 and 6&#x000a0;h after co-administration of prasugrel and placebo/morphine. VASP phosphorylation was measured by flow-cytometry (<italic>n</italic>&#x000a0;=&#x000a0;12) and the CADP-CT with the platelet function analyzer (<italic>n</italic>&#x000a0;=&#x000a0;12). Data present medians with 25th and 75th percentiles (minimum and maximum)</p></caption><graphic xlink:href="392_2015_927_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec4"><title>Assessment of pharmacokinetics and pharmacodynamics</title><p>Prasugrel effects were measured with the following assays: multiple electrode aggregometry [<xref ref-type="bibr" rid="CR26">26</xref>], where the intercept of the individual down-slope and the plateau phase was plotted graphically for the area under the curve (AUC) to estimate the onset of the maximum effect, and with the platelet function analyzer under high shear rates [<xref ref-type="bibr" rid="CR27">27</xref>], where the onset of the maximum effect was defined as the first of three consecutive measurements of &#x0003e;300&#x000a0;s.</p><p>To determine the vasodilator-stimulated phosphoprotein (VASP) phosphorylation state of the whole blood, a standardized flow cytometric assay (PLT VASP, BioCytex, Marseille, France) was used, initially described by Schwarz et al. [<xref ref-type="bibr" rid="CR28">28</xref>]. Blood samples collected in 3.8&#x000a0;% sodium citrate (BD Vacutainer, Becton&#x02013;Dickinson, Schwechat, Austria) were incubated in vitro with adenosine diphosphate and/or prostaglandin E1 (PGE1) before fixation. For the presentation of data, we used the median fluorescence intensity (MFI) as described earlier [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>Whole blood aggregation was determined by an impedance aggregometer (Multiple Platelet Function Analyzer/Multiplate Analyzer, Roche, Vienna, Austria). As recommended by the manufacturer, we used hirudin as an anticoagulant. When activated in the test cartridge, platelets attach onto metal electrodes and aggregate, resulting in increased electrical resistance. This change in impedance is recorded for 6&#x000a0;min and is proportional to platelet aggregation. Blood was diluted with saline solution (0.9&#x000a0;%) at a 1:1 ratio and incubated for 3&#x000a0;min. After stirring at 37&#x000a0;&#x000b0;C, analyses were performed using the agonists ADP (6.4&#x000a0;&#x000b5;M) and PGE1 (9.4&#x000a0;&#x000b5;M) (Dynabyte Medical, Munich, Germany). Results were expressed as areas under the curve of the aggregation tracing (AUC). Following the recommendations of the manufacturer and for simpler presentation purposes, we expressed the results as units (U) [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>Platelet plug formation under high shear rates (5000&#x02013;6000&#x000a0;s<sup>&#x02212;1</sup>) was quantified by the platelet function analyzer (PFA-100, Siemens Healthcare Diagnostics, Vienna, Austria). Blood samples were collected in 3.8&#x000a0;% sodium citrate. The PFA-100 measures the time required for occlusion of the aperture by platelet plugs, which is defined as closure time (CT). The maximum duration of a measurement is 300&#x000a0;s. The instrument aspirates a blood sample under constant vacuum from the sample reservoir through a capillary and a microscopic aperture (147&#x000a0;lm) cut into the membrane, which leads to high shear induced platelet plug formation. The membrane is coated with collagen/adenosine diphosphate (CADP). The P2Y-innovance cartridge, which is more sensitive to prasugrel, was used to follow the evolution of platelet inhibition under high shear rates over time. In addition, the CADP-CT was measured at baseline and after 6&#x000a0;h (reference range 65&#x02013;120&#x000a0;s) [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p>Plasma concentrations of prasugrel active metabolite were determined by liquid chromatography tandem mass spectrometry. Blood samples (6&#x000a0;mL) were collected in pre-cooled EDTA tubes (BD Vacutainer, Becton&#x02013;Dickinson, Schwechat, Austria). The blood samples were gently inverted and centrifuged within 30&#x000a0;min at 1400&#x000d7;<italic>g</italic> (15&#x000a0;min, 2&#x02013;8&#x000a0;&#x000b0;C) to separate the plasma. Aliquots were stored at &#x02212;80&#x000a0;&#x000b0;C and analyzed within 3&#x000a0;months. The applied system consisted of a Symbiosis ALIAS chromatographic system (Spark Holland B.V., Emmen, Netherlands) and an AB Sciex detector (QTRAP 5500, AB Sciex, Framingham, MA, USA). A published procedure [<xref ref-type="bibr" rid="CR32">32</xref>] was modified to perform the analyses.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p>The sample size calculation was based on our previously performed drug&#x02013;drug interaction trial with clopidogrel [<xref ref-type="bibr" rid="CR15">15</xref>]. Assuming a drop-out rate of 10&#x000a0;%, we calculated that we would need 12 subjects in a cross-over design to achieve 90&#x000a0;% power (&#x003b1;&#x000a0;=&#x000a0;0.05).</p><p>Pharmacokinetic calculations were made using Kinetica 2000<sup>&#x000ae;</sup> version 3.0 (InnaPhase Corporation, Philadelphia, Pennsylvania). As usual for drug interaction studies, the primary pharmacokinetic outcome variable was the AUC of prasugrel active metabolite; all other comparisons were considered secondary.</p><p>Data are presented as means for demographic data, and medians for outcome variables in the text. Changes in all outcome variables were compared by non-parametric Wilcoxon signed-rank tests, accounting for the skewed distributions of the measurements. To assess the robustness of results, a mixed-model was fitted to test for period and carry-over effects for the outcome variables, which showed a significant effect on these analyses.</p><p>Statistical calculations were performed using commercially available software (IBM SPSS Statistics<sup>&#x000ae;</sup>, Version 20, and SAS<sup>&#x000ae;</sup>, Version 9.3). In all cases, two-sided <italic>p</italic> values <underline>&#x0003c;</underline>0.05 were considered significant.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Demographic characteristics of subjects and adverse events</title><p>Healthy volunteers (seven males, five females; 11 Caucasian, one Asian) were 30&#x000a0;&#x000b1;&#x000a0;10&#x000a0;years of age, had 69&#x000a0;&#x000b1;&#x000a0;11&#x000a0;kg, and a body mass index of 23&#x000a0;&#x000b1;&#x000a0;3&#x000a0;kg/m<sup>2</sup>. No clinically relevant adverse events were observed after morphine injection, in particular no vomiting occurred.</p></sec><sec id="Sec8"><title>Pharmacokinetics</title><p>Morphine did not significantly reduce the total exposure as measured by the AUC<sub>0&#x02013;n</sub> (69,573 vs. 65,991&#x000a0;ng&#x000a0;&#x000d7;&#x000a0;h/mL, <italic>p</italic>&#x000a0;=&#x000a0;0.239), which was the primary study endpoint; i.e., the mean intra-individual difference was only 5&#x000a0;%. Morphine injection did not influence the time of maximal plasma concentrations of prasugrel active metabolite (30 vs. 38&#x000a0;min, <italic>p</italic>&#x000a0;=&#x000a0;0.798), corresponding to a mean intra-individual difference of only 1&#x000a0;min. Similarly, However, morphine reduced the <italic>C</italic><sub>max</sub> of prasugrel active metabolite by 31&#x000a0;% from 1388 to 951&#x000a0;ng/mL (<italic>p</italic>&#x000a0;=&#x000a0;0.019) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Pharmacokinetic parameters of prasugrel active metabolite after a loading dose of 60&#x000a0;mg</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Placebo</th><th align="left">Morphine</th><th align="left">
<italic>p</italic>&#x000a0;value</th></tr></thead><tbody><tr><td align="left">AUC<sub>0&#x02013;<italic>n</italic></sub> (ng&#x000a0;&#x000d7;&#x000a0;h/mL)</td><td align="left">69,573 (58,898&#x02013;92,962)</td><td align="left">65,991 (50,216&#x02013;88,390)</td><td char="." align="char">0.239</td></tr><tr><td align="left">
<italic>C</italic>
<sub>max</sub> (ng/mL)</td><td align="left">1388 (1116&#x02013;1507)</td><td align="left">951 (821&#x02013;1106)</td><td char="." align="char">0.019</td></tr><tr><td align="left">
<italic>T</italic>
<sub>max</sub> (min)</td><td align="left">30 (30&#x02013;45)</td><td align="left">38 (30&#x02013;60)</td><td char="." align="char">0.798</td></tr></tbody></table><table-wrap-foot><p>Values are medians (&#x000b1;interquartile range); <italic>n</italic>&#x000a0;=&#x000a0;12</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Pharmacodynamics</title><p>Whole blood aggregation was not influenced by morphine co-administration, showing maximum inhibition on average 30&#x02013;45&#x000a0;min after prasugrel intake (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Only one subject in each period needed 60&#x02013;75&#x000a0;min to reach near maximal platelet aggregation.</p><p>Co-administration of morphine slightly delayed the maximal inhibition of platelet plug formation under high shear rates (30 vs. 20&#x000a0;min), but significance is lost after correction for multiple comparisons (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p>No differences in the VASP phosphorylation state (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a) and in the conventional collagen/ADP induced closure times (CADP-CT) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b) were observed between periods 6&#x000a0;h after morphine injection.</p><p>In general, prasugrel reduced the median platelet reactivity index in the VASP assay within 6&#x000a0;h from a median of 83 to 15&#x000a0;% under placebo, and from 82 to 11&#x000a0;% after morphine (for both periods: <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a).</p><p>Prasugrel intake prolonged the CADP-CT 6&#x000a0;h after intake from a median of 92&#x02013;129&#x000a0;s under placebo and from 89 to 173&#x000a0;s when morphine was co-administered (for both periods: <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b).</p><p>No significant carry-over or period effects were observed for any of the outcome parameters.</p></sec></sec><sec id="Sec10"><title>Discussion</title><p>As prasugrel is a more potent P2Y<sub>12</sub>-inhibitor than clopidogrel [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] we hypothesized that it has the potential to overcome the pharmacodynamic problems of the recently described clopidogrel&#x02013;morphine interaction [<xref ref-type="bibr" rid="CR15">15</xref>] and characterized the PK/PD interaction between morphine and prasugrel.</p><p>Morphine did not reduce the total drug exposure as measured by the AUC<sub>0&#x02013;n</sub>, which was the primary study endpoint (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). A 25&#x000a0;% change in AUC is considered a mild to moderate interaction according to the classification of the US Food and Drug Administration [<xref ref-type="bibr" rid="CR33">33</xref>]. Our trial provided a power of 100&#x000a0;% to exclude even such a mild interaction.</p><p>Similarly, morphine injection did not retard the <italic>T</italic><sub>max</sub> of the prasugrel active metabolite (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>), although we achieved a power of 92&#x000a0;% to detect a 1&#x000a0;h delay. This is in contrast to an average 2&#x000a0;h delay in the <italic>T</italic><sub>max</sub> of clopidogrel active metabolite after morphine injection [<xref ref-type="bibr" rid="CR15">15</xref>]. However, morphine co-administration reduced the maximum plasma concentrations of prasugrel active metabolite by 31&#x000a0;% (with a power of 92&#x000a0;%) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). This could be clinically relevant if morphine reduced the pharmacodynamic effects of prasugrel. Even though co-administration of morphine resulted in a 10&#x000a0;min delay in reaching maximal inhibition of platelet plug formation under high shear rates (30 vs. 20&#x000a0;min), significance is lost after correction for multiple comparisons. Prasugrel maximally inhibited platelet function 30&#x02013;45&#x000a0;min after intake in both treatment periods (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p>In addition, the other platelet function tests such as whole blood aggregation, the VASP phosphorylation state or collagen/ADP induced closure times were not influenced by morphine (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref>). As all platelet assays consistently refute a significant impact of morphine on prasugrel effects, we were not able to prove a pharmacodynamic interaction of morphine with a 60&#x000a0;mg loading dose of prasugrel. The currently authorized loading dose of 60&#x000a0;mg prasugrel appears adequate to inhibit platelet function (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref>) in healthy volunteers, even when the maximal plasma concentrations of prasugrel active metabolite are reduced by ~30&#x000a0;% (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p>The active metabolites of prasugrel and clopidogrel have comparable anti-platelet activity in vitro. Hence, the higher in vivo potency of prasugrel reflects the more efficient generation of its active metabolite [<xref ref-type="bibr" rid="CR34">34</xref>]. This is also demonstrated by the current pharmacokinetic data, which show that maximal plasma concentrations and exposure to the active metabolite of prasugrel (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) are several-fold higher than that of clopidogrel [<xref ref-type="bibr" rid="CR15">15</xref>] despite the tenfold higher clopidogrel loading dose.</p><p>One limitation of the current randomized trial is the investigation of healthy volunteers rather than STEMI patients, whose gastrointestinal absorption may be further compromised, e.g., by reduced splanchnic blood flow [<xref ref-type="bibr" rid="CR35">35</xref>]. However, our cross-over design is considered most adequate for the detection of drug&#x02013;drug interactions [<xref ref-type="bibr" rid="CR33">33</xref>]. The resulting low intra-individual variability in such a cross-over design yields exclusively high power to exclude even mild interactions (100&#x000a0;% power for AUC) in a relatively limited sample size.</p><p>In conclusion, morphine co-administration moderately decreases the maximal plasma concentrations of prasugrel active metabolite but does not inhibit its effects on platelets to a clinically relevant degree in healthy volunteers.</p><p>Therefore, a 60&#x000a0;mg loading dose of prasugrel seems to be effective when morphine is given, but it should be considered that the observed changes in the maximum plasma concentrations of prasugrel active metabolite caused by morphine co-administration may gain relevance in STEMI patients.</p></sec></body><back><fn-group><fn><p>T. Stimpfl and B. Jilma contributed equally.</p></fn></fn-group><ack><p>Dr. Christa Firbas, Christa Drucker, Sabine Schranz, Karin Petroczi and Kurt Jiran are acknowledged for their assistance.</p></ack><notes notes-type="conflict-interest"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p>This work was supported by grant SFB-54 (P04) by the Austrian Science Funds (to BJ; for study conduct) and by the Medical-Scientific Fund of the Mayor of Vienna (15028 for analysis of prasugrel pharmacokinetics). The authors have no other conflicts of interest to report.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohrle</surname><given-names>J</given-names></name><name><surname>Bertrand</surname><given-names>B</given-names></name><name><surname>Sondergaard</surname><given-names>L</given-names></name><name><surname>Turner</surname><given-names>M</given-names></name><name><surname>Scholtz</surname><given-names>W</given-names></name><name><surname>Ibrahim</surname><given-names>R</given-names></name><name><surname>Bourlon</surname><given-names>F</given-names></name></person-group><article-title>PFO closuRE and CryptogenIc StrokE (PRECISE) registry: a multi-center, international registry</article-title><source>Clinical research in cardiology: official journal of the German Cardiac Society.</source><year>2012</year><volume>101</volume><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1007/s00392-012-0458-9</pub-id><pub-id pub-id-type="pmid">22487724</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clever</surname><given-names>YP</given-names></name><name><surname>Cremers</surname><given-names>B</given-names></name><name><surname>von Scheidt</surname><given-names>W</given-names></name><name><surname>Bohm</surname><given-names>M</given-names></name><name><surname>Speck</surname><given-names>U</given-names></name><name><surname>Scheller</surname><given-names>B</given-names></name></person-group><article-title>Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis</article-title><source>Clin Res Cardiol Off J Ger Card Soc</source><year>2014</year><volume>103</volume><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1007/s00392-013-0617-7</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budzynski</surname><given-names>J</given-names></name><name><surname>Kozinski</surname><given-names>M</given-names></name><name><surname>Klopocka</surname><given-names>M</given-names></name><name><surname>Kubica</surname><given-names>JM</given-names></name><name><surname>Kubica</surname><given-names>J</given-names></name></person-group><article-title>Clinical significance of <italic>Helicobacter pylori</italic> infection in patients with acute coronary syndromes: an overview of current evidence</article-title><source>Clin Res Cardiol Off J Ger Card Soc</source><year>2014</year><volume>103</volume><fpage>855</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1007/s00392-014-0720-4</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Waha</surname><given-names>S</given-names></name><name><surname>Eitel</surname><given-names>I</given-names></name><name><surname>Desch</surname><given-names>S</given-names></name><name><surname>Fuernau</surname><given-names>G</given-names></name><name><surname>Lurz</surname><given-names>P</given-names></name><name><surname>Urban</surname><given-names>D</given-names></name><name><surname>Schuler</surname><given-names>G</given-names></name><name><surname>Thiele</surname><given-names>H</given-names></name></person-group><article-title>Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging</article-title><source>Clin Res Cardiol Off J Ger Card Soc</source><year>2015</year><volume>104</volume><fpage>727</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1007/s00392-015-0835-2</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gremmel</surname><given-names>T</given-names></name><name><surname>Fruhwirth</surname><given-names>K</given-names></name><name><surname>Kopp</surname><given-names>CW</given-names></name><name><surname>Kaider</surname><given-names>A</given-names></name><name><surname>Steiner</surname><given-names>S</given-names></name><name><surname>Bakchoul</surname><given-names>T</given-names></name><name><surname>Sachs</surname><given-names>UJ</given-names></name><name><surname>Koppensteiner</surname><given-names>R</given-names></name><name><surname>Panzer</surname><given-names>S</given-names></name></person-group><article-title>Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity</article-title><source>Clin Res Cardiol Off J Ger Card Soc</source><year>2012</year><volume>101</volume><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1007/s00392-011-0411-3</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>R</given-names></name><name><surname>Kirchberger</surname><given-names>I</given-names></name><name><surname>Hunger</surname><given-names>M</given-names></name><name><surname>Heier</surname><given-names>M</given-names></name><name><surname>Leidl</surname><given-names>R</given-names></name><name><surname>von Scheidt</surname><given-names>W</given-names></name><name><surname>Meisinger</surname><given-names>C</given-names></name><name><surname>Holle</surname><given-names>R</given-names></name></person-group><article-title>Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines</article-title><source>Clin Res Cardiol Off J Ger Card Soc</source><year>2014</year><volume>103</volume><fpage>237</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1007/s00392-013-0643-5</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liosis</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>T</given-names></name><name><surname>Schiele</surname><given-names>R</given-names></name><name><surname>Gohlke</surname><given-names>H</given-names></name><name><surname>Gottwik</surname><given-names>M</given-names></name><name><surname>Katus</surname><given-names>H</given-names></name><name><surname>Sabin</surname><given-names>G</given-names></name><name><surname>Zahn</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Rauch</surname><given-names>B</given-names></name><name><surname>Senges</surname><given-names>J</given-names></name><name><surname>Zeymer</surname><given-names>U</given-names></name></person-group><article-title>Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study</article-title><source>Clin Res Cardiol Off J Ger Card Soc</source><year>2013</year><volume>102</volume><fpage>671</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1007/s00392-013-0581-2</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desch</surname><given-names>S</given-names></name><name><surname>Siegemund</surname><given-names>A</given-names></name><name><surname>Scholz</surname><given-names>U</given-names></name><name><surname>Adam</surname><given-names>N</given-names></name><name><surname>Eitel</surname><given-names>I</given-names></name><name><surname>de Waha</surname><given-names>S</given-names></name><name><surname>Furnau</surname><given-names>G</given-names></name><name><surname>Lurz</surname><given-names>P</given-names></name><name><surname>Wetzel</surname><given-names>S</given-names></name><name><surname>Schuler</surname><given-names>G</given-names></name><name><surname>Thiele</surname><given-names>H</given-names></name></person-group><article-title>Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction</article-title><source>Clin Res Cardiol Off J Ger Card Soc</source><year>2012</year><volume>101</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1007/s00392-011-0372-6</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zusman</surname><given-names>O</given-names></name><name><surname>Amit</surname><given-names>G</given-names></name><name><surname>Gilutz</surname><given-names>H</given-names></name><name><surname>Zahger</surname><given-names>D</given-names></name></person-group><article-title>The significance of new onset atrial fibrillation complicating acute myocardial infarction</article-title><source>Clin Res Cardiol Off J Ger Card Soc</source><year>2012</year><volume>101</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/s00392-011-0357-5</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeymer</surname><given-names>U</given-names></name><name><surname>Arntz</surname><given-names>HR</given-names></name><name><surname>Mark</surname><given-names>B</given-names></name><name><surname>Fichtlscherer</surname><given-names>S</given-names></name><name><surname>Werner</surname><given-names>G</given-names></name><name><surname>Scholler</surname><given-names>R</given-names></name><name><surname>Zahn</surname><given-names>R</given-names></name><name><surname>Diller</surname><given-names>F</given-names></name><name><surname>Darius</surname><given-names>H</given-names></name><name><surname>Dill</surname><given-names>T</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name></person-group><article-title>Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial</article-title><source>Clin Res Cardiol Off J Ger Card Soc</source><year>2012</year><volume>101</volume><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1007/s00392-011-0393-1</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivier</surname><given-names>CB</given-names></name><name><surname>Schnabel</surname><given-names>K</given-names></name><name><surname>Brandt</surname><given-names>C</given-names></name><name><surname>Weik</surname><given-names>P</given-names></name><name><surname>Olschewski</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Bode</surname><given-names>C</given-names></name><name><surname>Diehl</surname><given-names>P</given-names></name><name><surname>Moser</surname><given-names>M</given-names></name></person-group><article-title>A high ratio of ADP&#x02013;TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone</article-title><source>Clin Res Cardiol Off J Ger Card Soc</source><year>2014</year><volume>103</volume><fpage>968</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1007/s00392-014-0737-8</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>James</surname><given-names>S</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Ardissino</surname><given-names>D</given-names></name><name><surname>Becker</surname><given-names>RC</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Emanuelsson</surname><given-names>H</given-names></name><name><surname>Finkelstein</surname><given-names>A</given-names></name><name><surname>Husted</surname><given-names>S</given-names></name><name><surname>Katus</surname><given-names>H</given-names></name><name><surname>Kilhamn</surname><given-names>J</given-names></name><name><surname>Olofsson</surname><given-names>S</given-names></name><name><surname>Storey</surname><given-names>RF</given-names></name><name><surname>Weaver</surname><given-names>WD</given-names></name><name><surname>Wallentin</surname><given-names>L</given-names></name></person-group><article-title>Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>2131</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.927582</pub-id><pub-id pub-id-type="pmid">21060072</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meine</surname><given-names>TJ</given-names></name><name><surname>Roe</surname><given-names>MT</given-names></name><name><surname>Chen</surname><given-names>AY</given-names></name><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Washam</surname><given-names>JB</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Peacock</surname><given-names>WF</given-names></name><name><surname>Pollack</surname><given-names>CV</given-names><suffix>Jr</suffix></name><name><surname>Gibler</surname><given-names>WB</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name></person-group><article-title>Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE quality improvement initiative</article-title><source>Am Heart J</source><year>2005</year><volume>149</volume><fpage>1043</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2005.02.010</pub-id><pub-id pub-id-type="pmid">15976786</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nimmo</surname><given-names>WS</given-names></name><name><surname>Heading</surname><given-names>RC</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name><name><surname>Tothill</surname><given-names>P</given-names></name><name><surname>Prescott</surname><given-names>LF</given-names></name></person-group><article-title>Inhibition of gastric emptying and drug absorption by narcotic analgesics</article-title><source>Br J Clin Pharmacol</source><year>1975</year><volume>2</volume><fpage>509</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1975.tb00568.x</pub-id><pub-id pub-id-type="pmid">9953</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobl</surname><given-names>EL</given-names></name><name><surname>Stimpfl</surname><given-names>T</given-names></name><name><surname>Ebner</surname><given-names>J</given-names></name><name><surname>Schoergenhofer</surname><given-names>C</given-names></name><name><surname>Derhaschnig</surname><given-names>U</given-names></name><name><surname>Sunder-Plassmann</surname><given-names>R</given-names></name><name><surname>Jilma-Stohlawetz</surname><given-names>P</given-names></name><name><surname>Mannhalter</surname><given-names>C</given-names></name><name><surname>Posch</surname><given-names>M</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name></person-group><article-title>Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>63</volume><fpage>630</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.10.068</pub-id><pub-id pub-id-type="pmid">24315907</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abell</surname><given-names>LM</given-names></name><name><surname>Liu</surname><given-names>EC</given-names></name></person-group><article-title>Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro</article-title><source>J Pharmacol Exp Ther</source><year>2011</year><volume>339</volume><fpage>589</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1124/jpet.111.184895</pub-id><pub-id pub-id-type="pmid">21828263</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farid</surname><given-names>NA</given-names></name><name><surname>Kurihara</surname><given-names>A</given-names></name><name><surname>Wrighton</surname><given-names>SA</given-names></name></person-group><article-title>Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans</article-title><source>J Clin Pharmacol</source><year>2010</year><volume>50</volume><fpage>126</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1177/0091270009343005</pub-id><pub-id pub-id-type="pmid">19948947</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dansette</surname><given-names>PM</given-names></name><name><surname>Rosi</surname><given-names>J</given-names></name><name><surname>Debernardi</surname><given-names>J</given-names></name><name><surname>Bertho</surname><given-names>G</given-names></name><name><surname>Mansuy</surname><given-names>D</given-names></name></person-group><article-title>Metabolic activation of prasugrel: nature of the two competitive pathways resulting in the opening of its thiophene ring</article-title><source>Chem Res Toxicol</source><year>2012</year><volume>25</volume><fpage>1058</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1021/tx3000279</pub-id><pub-id pub-id-type="pmid">22482514</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>OO</given-names></name><name><surname>Angiolillo</surname><given-names>DJ</given-names></name><name><surname>Ferreiro</surname><given-names>JL</given-names></name><name><surname>Jakubowski</surname><given-names>JA</given-names></name><name><surname>Winters</surname><given-names>KJ</given-names></name><name><surname>Effron</surname><given-names>MB</given-names></name><name><surname>Duvvuru</surname><given-names>S</given-names></name><name><surname>Costigan</surname><given-names>TM</given-names></name><name><surname>Sundseth</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>JR</given-names></name><name><surname>Saucedo</surname><given-names>JF</given-names></name><name><surname>Kleiman</surname><given-names>NS</given-names></name><name><surname>Varenhorst</surname><given-names>C</given-names></name></person-group><article-title>Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways</article-title><source>Thromb Haemost</source><year>2013</year><volume>110</volume><fpage>1223</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1160/TH13-03-0263</pub-id><pub-id pub-id-type="pmid">24009042</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siller-Matula</surname><given-names>JM</given-names></name><name><surname>Krumphuber</surname><given-names>J</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name></person-group><article-title>Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases</article-title><source>Br J Pharmacol</source><year>2010</year><volume>159</volume><fpage>502</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00555.x</pub-id><pub-id pub-id-type="pmid">20050853</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandt</surname><given-names>JT</given-names></name><name><surname>Payne</surname><given-names>CD</given-names></name><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Weerakkody</surname><given-names>G</given-names></name><name><surname>Farid</surname><given-names>NA</given-names></name><name><surname>Small</surname><given-names>DS</given-names></name><name><surname>Jakubowski</surname><given-names>JA</given-names></name><name><surname>Naganuma</surname><given-names>H</given-names></name><name><surname>Winters</surname><given-names>KJ</given-names></name></person-group><article-title>A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation</article-title><source>Am Heart J</source><year>2007</year><volume>153</volume><issue>66</issue><fpage>e9</fpage><lpage>e16</lpage><pub-id pub-id-type="pmid">17174640</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siller-Matula</surname><given-names>JM</given-names></name><name><surname>Trenk</surname><given-names>D</given-names></name><name><surname>Schror</surname><given-names>K</given-names></name><name><surname>Gawaz</surname><given-names>M</given-names></name><name><surname>Kristensen</surname><given-names>SD</given-names></name><name><surname>Storey</surname><given-names>RF</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name></person-group><article-title>Response variability to P2Y12 receptor inhibitors: expectations and reality</article-title><source>JACC Cardiovasc interv</source><year>2013</year><volume>6</volume><fpage>1111</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1016/j.jcin.2013.06.011</pub-id><pub-id pub-id-type="pmid">24262612</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aradi</surname><given-names>D</given-names></name><name><surname>Komocsi</surname><given-names>A</given-names></name><name><surname>Vorobcsuk</surname><given-names>A</given-names></name><name><surname>Serebruany</surname><given-names>VL</given-names></name></person-group><article-title>Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis</article-title><source>Thromb Haemost</source><year>2013</year><volume>109</volume><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1160/TH12-06-0377</pub-id><pub-id pub-id-type="pmid">23197191</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saucedo</surname><given-names>JF</given-names></name><name><surname>Angiolillo</surname><given-names>DJ</given-names></name><name><surname>DeRaad</surname><given-names>R</given-names></name><name><surname>Frelinger</surname><given-names>AL</given-names><suffix>3rd</suffix></name><name><surname>Gurbel</surname><given-names>PA</given-names></name><name><surname>Costigan</surname><given-names>TM</given-names></name><name><surname>Jakubowski</surname><given-names>JA</given-names></name><name><surname>Ojeh</surname><given-names>CK</given-names></name><name><surname>Duvvuru</surname><given-names>S</given-names></name><name><surname>Effron</surname><given-names>MB</given-names></name></person-group><article-title>Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study</article-title><source>Thromb Haemost</source><year>2013</year><volume>109</volume><fpage>347</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1160/TH12-06-0378</pub-id><pub-id pub-id-type="pmid">23223867</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurbel</surname><given-names>PA</given-names></name><name><surname>Bliden</surname><given-names>KP</given-names></name><name><surname>Butler</surname><given-names>K</given-names></name><name><surname>Tantry</surname><given-names>US</given-names></name><name><surname>Gesheff</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>C</given-names></name><name><surname>Teng</surname><given-names>R</given-names></name><name><surname>Antonino</surname><given-names>MJ</given-names></name><name><surname>Patil</surname><given-names>SB</given-names></name><name><surname>Karunakaran</surname><given-names>A</given-names></name><name><surname>Kereiakes</surname><given-names>DJ</given-names></name><name><surname>Parris</surname><given-names>C</given-names></name><name><surname>Purdy</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>V</given-names></name><name><surname>Ledley</surname><given-names>GS</given-names></name><name><surname>Storey</surname><given-names>RF</given-names></name></person-group><article-title>Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study</article-title><source>Circulation</source><year>2009</year><volume>120</volume><fpage>2577</fpage><lpage>2585</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.912550</pub-id><pub-id pub-id-type="pmid">19923168</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siller-Matula</surname><given-names>JM</given-names></name><name><surname>Christ</surname><given-names>G</given-names></name><name><surname>Lang</surname><given-names>IM</given-names></name><name><surname>Delle-Karth</surname><given-names>G</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name></person-group><article-title>Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay</article-title><source>J Thromb Haemost</source><year>2010</year><volume>8</volume><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2009.03699.x</pub-id><pub-id pub-id-type="pmid">19943879</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>I</given-names></name><name><surname>Frossard</surname><given-names>M</given-names></name><name><surname>Spiel</surname><given-names>A</given-names></name><name><surname>Riedmuller</surname><given-names>E</given-names></name><name><surname>Laggner</surname><given-names>AN</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name></person-group><article-title>Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS</article-title><source>J Thromb Haemost</source><year>2006</year><volume>4</volume><fpage>2547</fpage><lpage>2552</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2006.02239.x</pub-id><pub-id pub-id-type="pmid">17002662</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>UR</given-names></name><name><surname>Geiger</surname><given-names>J</given-names></name><name><surname>Walter</surname><given-names>U</given-names></name><name><surname>Eigenthaler</surname><given-names>M</given-names></name></person-group><article-title>Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets&#x02013;definition and detection of ticlopidine/clopidogrel effects</article-title><source>Thromb Haemost</source><year>1999</year><volume>82</volume><fpage>1145</fpage><lpage>1152</lpage><pub-id pub-id-type="pmid">10494779</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiel</surname><given-names>AO</given-names></name><name><surname>Derhaschnig</surname><given-names>U</given-names></name><name><surname>Schwameis</surname><given-names>M</given-names></name><name><surname>Bartko</surname><given-names>J</given-names></name><name><surname>Siller-Matula</surname><given-names>JM</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name></person-group><article-title>Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial</article-title><source>Clin Sci</source><year>2012</year><volume>123</volume><fpage>591</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1042/CS20120194</pub-id><pub-id pub-id-type="pmid">22646240</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiel</surname><given-names>AO</given-names></name><name><surname>Bartko</surname><given-names>J</given-names></name><name><surname>Schwameis</surname><given-names>M</given-names></name><name><surname>Firbas</surname><given-names>C</given-names></name><name><surname>Siller-Matula</surname><given-names>J</given-names></name><name><surname>Schuetz</surname><given-names>M</given-names></name><name><surname>Weigl</surname><given-names>M</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name></person-group><article-title>Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration. A randomised controlled trial</article-title><source>Thromb Haemost</source><year>2011</year><volume>105</volume><fpage>655</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1160/TH10-08-0530</pub-id><pub-id pub-id-type="pmid">21301783</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiel</surname><given-names>AO</given-names></name><name><surname>Siller-Matula</surname><given-names>J</given-names></name><name><surname>Firbas</surname><given-names>C</given-names></name><name><surname>Leitner</surname><given-names>JM</given-names></name><name><surname>Russmueller</surname><given-names>G</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name></person-group><article-title>Single dose granulocyte colony-stimulating factor markedly enhances shear-dependent platelet function in humans</article-title><source>Platelets</source><year>2010</year><volume>21</volume><fpage>464</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.3109/09537104.2010.485255</pub-id><pub-id pub-id-type="pmid">20528259</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farid</surname><given-names>NA</given-names></name><name><surname>McIntosh</surname><given-names>M</given-names></name><name><surname>Garofolo</surname><given-names>F</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name><name><surname>Shwajch</surname><given-names>A</given-names></name><name><surname>Kennedy</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>M</given-names></name><name><surname>Sarkar</surname><given-names>P</given-names></name><name><surname>Kawabata</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Pang</surname><given-names>H</given-names></name></person-group><article-title>Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry</article-title><source>Rapid Commun Mass Spectrom</source><year>2007</year><volume>21</volume><fpage>169</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1002/rcm.2813</pub-id><pub-id pub-id-type="pmid">17154350</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SM</given-names></name><name><surname>Temple</surname><given-names>R</given-names></name><name><surname>Throckmorton</surname><given-names>DC</given-names></name><name><surname>Lesko</surname><given-names>LJ</given-names></name></person-group><article-title>Drug interaction studies: study design, data analysis, and implications for dosing and labeling</article-title><source>Clin Pharmacol Ther</source><year>2007</year><volume>81</volume><fpage>298</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1038/sj.clpt.6100054</pub-id><pub-id pub-id-type="pmid">17259955</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugidachi</surname><given-names>A</given-names></name><name><surname>Ogawa</surname><given-names>T</given-names></name><name><surname>Kurihara</surname><given-names>A</given-names></name><name><surname>Hagihara</surname><given-names>K</given-names></name><name><surname>Jakubowski</surname><given-names>JA</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Niitsu</surname><given-names>Y</given-names></name><name><surname>Asai</surname><given-names>F</given-names></name></person-group><article-title>The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel&#x02019;s active metabolite</article-title><source>J Thromb Haemost</source><year>2007</year><volume>5</volume><fpage>1545</fpage><lpage>1551</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2007.02598.x</pub-id><pub-id pub-id-type="pmid">17456192</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bochner</surname><given-names>F</given-names></name><name><surname>Lloyd</surname><given-names>JV</given-names></name></person-group><article-title>Aspirin for myocardial infarction. Clinical pharmacokinetic considerations</article-title><source>Clin Pharmacokinet</source><year>1995</year><volume>28</volume><fpage>433</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.2165/00003088-199528060-00001</pub-id><pub-id pub-id-type="pmid">7656501</pub-id></element-citation></ref></ref-list></back></article>